Associate Editor, Ophthalmology Times
Regeneron announces publication of one-year results from PULSAR and PHOTON trials
March 8th 2024Results show Eylea HD extended dosing regimens were non-inferior to aflibercept 2 mg injection (Eylea) for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
Read More
Importance of early screening for diabetic retinopathy and other diagnostic options
March 8th 2024John Bertrand, CEO of Digital Diagnostics sits down with Managing Editor David Hutton of Ophthalmology Times to talk about the importance of early screening for diabetic retinopathy as well as other diagnostic options for National Save Your Vision month.
Read More
TL-925 is a first in class, topical Bruton’s tyrosine kinase (BTK) inhibitor that prevents mast cell activation and degranulation, and also blocks the cytokine-driven inflammatory response, and restores lacrimal unit homeostasis, offering the potential for disease modification
Read More
AGS 2024: Bridging the language barrier in eye care
March 2nd 2024David Sola-Del Valle, MD, sat down with David Hutton of Ophthalmology Times to discuss his talk at the annual American Glaucoma Society meeting held in Huntington Beach, about the importance of bridging the language barrier in patients who may not be fluent in English.
Read More
AGS 2024: Tips for implementing telehealth into ophthalmology
March 1st 2024April Maa, MD, sat down with David Hutton of Ophthalmology Times to discuss her presentation at the annual American Glaucoma Society meeting held in Huntington Beach, about tips and tricks for implementing telehealth into ophthalmology.
Read More
AGS 2024: Travoprost intraocular implant safe and effective in phakic eyes
February 29th 2024Steven R. Sarkisian, MD, sat down with David Hutton of Ophthalmology Times to discuss his poster about the Travoprost intraocular implant in phakic eyes from the American Glaucoma Society meeting held in Huntington Beach
Read More
AGS 2024: Travoprost intraocular implant in OAG and OHT subjects
February 29th 2024I. Paul Singh, MD, sat down with David Hutton of Ophthalmology Times to discuss his poster "Travoprost Intraocular Implant Demonstrates Efficacy in Diverse Subpopulations of OAG and OHT Subjects," from the American Glaucoma Society meeting held in Huntington Beach
Read More
Fortifeye launches Eye Pressure and Neuro Cognitive Support supplement
February 29th 2024The supplement is specifically crafted to promote healthy intraocular pressure (IOP), nurturing the well-being of retinal ganglion cells, and sustain the health of the retinal nerve fiber layer while boosting memory and concentration.
Read More
AGS 2024: Leon Herndon, MD, President of AGS, previews the annual meeting
February 29th 2024Leon Herndon, MD, President of the American Glaucoma Society, sat down with David Hutton of Ophthalmology Times to discuss the AGS meeting held in Huntington Beach and what attendees can expect as well as new and exciting information to come from the meeting.
Read More
Kathryn A. Colby, MD, PhD, looks to the future in ophthalmology and at NYU
February 16th 2024David Hutton of Ophthalmology Times talks with Kathryn A. Colby, MD, PhD, Elisabeth J. Cohen Professor and Chair, NYU Langone Department of Ophthalmology, about the year the department had in 2023 as well as an outlook at advancements in the field of ophthalmology moving forward.
Read More
Kiora Pharmaceuticals CEO discusses partnership with Théa Open Innovation and pipeline updates
February 12th 2024David Hutton of Ophthalmology Times talks with Brian Strem, PhD, CEO Kiora Pharmaceuticals, about their recent partnership with Théa Open Innovation and further development of their KIO-301 and KOI-104 programs.
Read More
Glaucoma 360: Innovations in glaucoma drugs and drug delivery
February 10th 2024Joseph Panarelli, MD, sat down with David Hutton of Ophthalmology Times to discuss the panel he moderated at the Glaucoma 360 meeting held in San Francisco, about innovations in glaucoma drugs, and drug delivery.
Read More
Kyowa Kirin enrolls first patient in phase 2 trial of drops for treatment of diabetic macular edema
February 9th 2024The trial will evaluate tivozanib eye drops (KHK4951), a small-molecule vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor (TKI), in patients in with DME.
Read More
Angiogenesis 2024: AVD-104 for Geographic Atrophy
February 3rd 2024Carl Danzig, MD, sat down with Martin David Harp of Ophthalmology Times to discuss his presentation AVD-104 for Geographic Atrophy: Glyco-immunologic modulation of macrophage activity from the Angiogenesis Exudation and Degeneration 2024 event.
Read More
Angiogenesis 2024: Precursor lesions for development of atrophy and AMD
February 3rd 2024SriniVas R. Sadda, MD, sat down with David Hutton of Ophthalmology Times to discuss his presentation about precursor lesions for development of atrophy and AMD from the Angiogenesis Exudation and Degeneration 2024 event.
Read More
President and CEO of Ashvattha Therapeutics talks about the company's unique nanomedicine technology
January 28th 2024David Hutton of Ophthalmology Times talks with Jeffrey Cleland, PhD, President and CEO of Ashvattha Therapeutics, about the company's D-4517.2, a unique nanomedicine technology for the treatment of wet AMD and DME.
Read More